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Abstract
Recurrence and drug resistance of breast cancer are still the main reasons for breast cancer-associated deaths. Cancer stem
cell (CSC) model has been proposed as a hypothesis for the lethality of breast cancer. Molecular mechanisms underlying
CSC maintenance are still unclear. In this study, we generated mammospheres derived from breast cancer MDA-MB231
cells and MCF7 cells to enrich CSCs and performed DNA microarray analysis. We found that the expression of carboxy
terminus of HSP70-interacting protein (CHIP) E3 ubiquitin ligase was signiﬁcantly downregulated in breast CSCs. CHIP
depletion increased mammosphere formation, whereas CHIP overexpression reversed this effect. We identiﬁed interactomes
by mass spectrometry and detected CHIP directly interacted with OCT4, a stemness factor. CHIP overexpression decreased
OCT4 stability through proteasomal degradation. CHIP induced OCT4 ubiquitination, whereas H260Q, a catalytic CHIP
mutant, did not. Interestingly, we determined that OCT4 was ubiquitinated at lysine 284, and CHIP overexpression did not
degrade K284R mutant OCT4. CHIP overexpression decreased the proliferation and side population of breast cancer cells,
but these were not occurred in K284R mutant OCT4 overexpressed cells. Only 1000 cells showing CHIP depletion or OCT4
overexpression sufﬁciently generated breast tumors and lung metastases in xenografted mice. Ubiquitination-defective
mutant of OCT4(K284R) overexpressed cells drastically generated tumor burdens in mice. Patients with breast cancer who
showed low CHIP expression had poor survival probability. Taken together, we suggest that CHIP-induced OCT4
ubiquitination is important in breast CSCs. Regulation of CHIP expression and OCT4 protein stability is a considerable
approach for breast cancer therapy.
Introduction
Breast cancer is the second leading cause of cancer death in
women [1]. Therapeutic advancement has substantially
improved 5-year survival rate in patients with breast cancer;
however, recurrence and subsequent drug resistance are the
main cause of breast cancer-related deaths [2]. Breast cancer
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lethality can be explained using a cancer stem cell (CSC)
model, which suggests that malignancies arise from a small
subset of CSCs [3]. Aggressive tumors contain higher
proportion of CSCs than benign tumors, and tumor malig-
nancy is correlated with CSC proportion. Like stem cell
regulatory pathways, Wnt/β-catenin, Notch, Hedgehog, and
bone morphogenetic protein pathways play important roles
in CSC regulation [4]. Potential CSC markers include cell
surface receptors such as CD133, CD44, and EpCAM;
enzymes such as aldehyde dehydrogenase; and transcrip-
tional factors such as SRY-box 2 (SOX2), Nanog homeo-
box (Nanog), and POU class 5 homeobox 1 (POU5F1 or
OCT3/4) [5]. However, limited evidence is available on
CSCs and on mechanisms underlying CSC maintenance in
tumors [6]. Therefore, we characterized breast CSCs by
establishing mammosphere cultures. Because CSCs likely
are a small population of cells among cancer cells, mam-
mosphere cultures can be established to identify and to
enrich CSCs [7]. Dontu et al. showed that serum-free non-
adherent cultures enrich breast stem cells within a popula-
tion of primary human mammary epithelial cells [8]. This
technique was used to enrich CSCs from breast cancer cells.
In this study, we generated mammospheres from MCF7 and
MDA-MB231 breast cancer cells and performed DNA micro-
array analysis to identify the regulator of breast cancer CSCs.
We assessed the expression levels of E3 ubiquitin ligases to
determine the role of protein stability and homeostasis in CSC
maintenance. We found that carboxy terminus of HSP70-
interacting protein (CHIP), an E3 ubiquitin ligase, was sig-
niﬁcantly downregulated in mammospheres derived from
MCF7 and MDA-MB231 cells. CHIP is involved in cellular
processes such as protein trafﬁcking, degradation, signaling,
transcription, and apoptosis [9]. CHIP functions as a chaperone-
associated E3 ligase for several proteins and regulates various
physiological processes, such as cancers, neurological disorders,
cardiac diseases, and bone metabolism [10]. The role of CHIP
in cancers is controversial because it is suggested to exert both
oncogenic and tumor-suppressive effects. In nude mice with
breast tumors, tumor growth and metastasis are negatively
correlated with CHIP levels [11]. CHIP seems to regulate the
levels of several well-known oncogenic proteins such as
TRAF2, NF-ƙB, PTK6, and MIF [12–14]. Further, CHIP
degrades several critical oncoproteins such as AKT, MYC, and
HIF-1α in various cancers [15–17], indicating its tumor-
suppressive role. However, several studies have reported the
oncogenic role of CHIP. CHIP promotes the ubiquitination and
degradation of FoxO1, antagonizes FoxO1-mediated proa-
poptotic signaling, and enhances survival and proliferation of
cells [18]. PTEN is a target of CHIP-mediated ubiquitination
and degradation in prostate cancer cells [19]. However, the
exact role of CHIP in CSCs is not elucidated, yet.
In this study, we determined mechanisms underlying CSC
maintenance in breast tumors. We found that breast CSCs
showed downregulation of CHIP expression and regulation
of post-translational modiﬁcation of OCT4, a stemness fac-
tor, because OCT4 dosage is important for determining cell
fate of embryonic stem cells and cancer tumorigenesis.
Moreover, we determined how downregulation of CHIP
regulates OCT4 expression in CSCs and in breast tumor-
igenesis, and whether regulation of OCT4 stability is a rea-
sonable approach for breast cancer therapy.
Results
CHIP E3 ligase is downregulated in mammospheres
derived from MCF7 and MDA-MB231 breast cancer
cells
We generated mammospheres from MDA-MB231 and
MCF7 cells and determined the alternative expression of E3
ligases by performing DNA microarray analysis (Fig. 1a).
We focused on CHIP downregulation. CHIP expression
was signiﬁcantly decreased in serial mammosphere cultures
and was restored in re-adherent cultures (Fig. 1b).
Next, we generated stable CHIP-overexpressing cells and
three CHIP-depleted cell types (Fig. 1c) and analyzed their
mammosphere-forming ability (Fig. 1d,e). CHIP-overexpressing
MDA-MB231 or MCF7 cells generated less number of mam-
mospheres that were smaller in size than those generated by
parent cells. In contrast, CHIP-depleted MDA-MB231 or MCF7
cells generated four-times higher number of mammosphere that
were larger than those generated by parent cells.
CHIP E3 ligase interacts with OCT4 and induces its
proteasomal degradation
We identiﬁed CHIP-interacting proteins in FLAG-tagged
CHIP-expressing MDA-MB231 cells by mass spectrometry
analysis (Fig. 2a). From a total of 641 unique proteins identiﬁed,
we selected CHIP-interacting proteins with exception of IgG-
speciﬁc and keratin proteins, and integrated the CHIP-speciﬁc
proteins into the protein interaction network using the Ingenuity
Pathway Analysis (IPA) software. The IPA software generated
the development-related proteins that are associated with CHIP
(Supplementary Fig. S1). Interestingly, some CHIP-interacting
proteins were associated with the self-renewal and stemness of
cells, and CHIP appeared to be interacted with OCT4 (Fig. 2b).
Firstly, we analyzed the public data (Kaplan–Meier plot ana-
lysis) to examine the correlation between OCT4 expression and
survival probability (Supplementary Fig. S2). Patients with
breast cancer showing high OCT4 expression showed poor
post-progression survival, suggesting that OCT4 expression is a
reliable marker for tumor progression and survival of patients
with breast cancer.
To determine whether CHIP regulated OCT4 stability, we
examined OCT4 expression in the absence of CHIP. Compared
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with scRNA-transfected cells, OCT4 levels increased in CHIP-
depleted cells in an mRNA-independent manner (Fig. 2c). CHIP
depletion did not signiﬁcantly affect the mRNA and protein
expression of Nanog and SOX2, suggesting that OCT4 is a
direct target of CHIP. We also quantitated the protein changes by
CHIP silencing (Fig. 2c below).
Overexpression of CHIP decreased OCT4 protein
expression in an mRNA-independent manner, and treatment
with proteasome inhibitor MG132 restored OCT4 levels
(Fig. 2d). Protein levels of OCT4 reduced in CHIP-
overexpressing cells treated with protein synthesis inhi-
bitor cycloheximide (CHX) (Supplementary Fig. S3A), and
were correlated with the concentration of CHIP transfected
(Fig. 2e). These data suggest that CHIP regulates OCT4 st-
ability through proteasomal degradation.
CHIP E3 ligase interacts with OCT4 in a chaperon-
dependent manner
Interaction of CHIP with OCT4 was conﬁrmed in MDA-
MB231 cells (Fig. 3a). Notably, OCT4 did not interact with
tetratricopeptide repeat (TPR) domain-mutated CHIP
(K30A) but interacted with wild-type (WT) CHIP or its E3
ligase functional negative catalytic site mutant H260Q
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Fig. 1 CHIP expression affects mammosphere-forming ability. a
Expression of different E3 ligases was compared by performing
microarray analysis of MDA-MB-231 and MCF7 cells in mammo-
sphere and normal cultures. b CHIP expression level was detected by
performing qRT-PCR (upper) and western blotting (lower). GAPDH
was used as a loading control. c The cells were infected with lentiviral
vectors to generate the indicated stable cell lines. CHIP overexpression
and depletion were conﬁrmed by performing western blotting. d
Mammosphere-forming ability of the stable cell lines was measured
for 15 days under sphere-forming conditions, and (e) the number of
spheres formed was quantiﬁed. Data are presented as mean ± SD (n=
3). Signiﬁcant differences are indicated by an asterisk (*p < 0.05); p
values were calculated using Student’s t test
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(Fig. 3b). This suggested that the interaction between CHIP
and OCT4 was mediated by chaperone proteins because
CHIP contains an HSP70 and HSP90 complex-interacting
E3 ligase at the TPR domain [20]. We treated MDA-MB
231 and MCF7 cells with an HSP90 inhibitor 17-AAG. 17-
AAG treatment signiﬁcantly decreased OCT4 levels but did
A B
Sox2
Nanog
MDA-MB231 MCF7
OCT4
GAPDH
CHIP
C
GAPDH
Oct4
SOX2
NANOG
35kDa
45kDa
35kDa
35kDa
45kDa
200bp
185bp
198bp
202bp Oct4
Oct4
MDA-MB231
GAPDH
CHIP
GAPDH
D
FLAG_CHIP
MG132 - - + +
- + - +
MCF7
- - + +
- + - +
35kDa
45kDa
35kDa
200bp
202bp
E MCF7
FLAG
OCT4
FLAG_CHIP
CHX + + + + + + + +
MDA-MB-231
GAPDH
35kDa
35kDa
45kDa
1784 Y. Cho et al.
Ofﬁcial journal of the Cell Death Differentiation Association
not affect CHIP expression (Supplementary Fig. S3B). WT
CHIP overexpression decreased OCT4 stability, whereas
K30A and H260Q mutant CHIP overexpression did not
affect OCT4 stability (Fig. 3c). CHIP depletion restored 17-
AAG-induced decrease in OCT4 expression (Supplemen-
tary Fig. S3C).
CHIP E3 ligase induces OCT4 ubiquitination
Overexpression of CHIP E3 ligase functional negative
catalytic site mutant H260Q stabilized OCT4 protein
expression (Fig. 3c). Next, we performed ubiquitination
assay under denaturing condition. CHIP depletion
decreased polyubiquitinated OCT4 levels in both MDA-
MB231 (Fig. 3d) and MCF7 cells (Suppl.Fig. S4A),
whereas CHIP overexpression increased polyubiquitinated
OCT4 levels in both MDA-MB231 (Fig. 3e) and MCF7
cells (Suppl.Fig. S4B). Compared to WT CHIP over-
expression increased, H260Q mutant CHIP overexpression
signiﬁcantly decreased, and K30A mutant CHIP over-
expression decreased polyubiquitinated OCT4 levels in
both MDA-MB231 (Fig. 3f) and MCF7 cells (Suppl.
Fig. S4C). These data suggest that CHIP induces OCT4
ubiquitination and degradation.
CHIP E3 ligase ubiquitinates OCT4 at lysine 284
From Mass spectrometric analysis of OCT4, we identiﬁed
the ubiquitination site at lysine 284 (K284), suggesting that
CHIP mediates ubiquitination of OCT4 (Fig. 4a). We fur-
ther conﬁrmed K284 as the predicted ubiquitination site in
OCT4 using BDM-PUB which is a prediction program for
potential ubiquitination sites in proteins (Suppl.Fig. S5). To
determine whether CHIP decreased OCT4 stability through
K284 ubiquitination, we generated endogenous OCT4-
depleted stable MDA-MB231 or MCF7 cells (OCT4KD
cells) (Supplementary Fig. S6A). We then generated an
ubiquitination-defective mutant of OCT4 (OCT4_K284R),
and overexpressed WT OCT4 or OCT4_K284R in the
endogenous OCT4-depleted cells (OCT4KD cells). As
shown in Fig. 4b, the interaction with WT OCT4 or
OCT4_K284R and CHIP were detected by immunopreci-
pitation assay. Compared to OCT4 degradation after co-
overexpression of CHIP, overexpression of OCT4_K284R
did not show OCT4 degradation by co-overexpression of
CHIP in OCT4KD cells (Fig. 4c). Proteosomal degradation
of OCT4 was not detected after overexpression of
OCT4_K284R in OCT4KD cells (Supplementary Fig. S6B).
Moreover, CHIP overexpression did not increase poly-
ubiquitinated OCT4_K284R levels compared to WT-OCT4
levels (Fig. 4d). These data indicate that CHIP poly-
ubiquitinates OCT4 at K284. We also determined in vitro
ubiquitination assay with CHIP and mutant OCT4_K284R
and CHIP ubiquitinated wild-type OCT4, whereas it could
not ubiquitinate mutant OCT4_K284R (Supplementary
Fig. S7).
CHIP E3 ligase overexpression decreases CSC
population through OCT4 ubiquitination
We measured the transcriptional activity of the OCT4 pro-
moter to check whether CHIP regulated the transcriptional
activity of OCT4. CHIP depletion increased OCT4 tran-
scriptional activity, whereas CHIP overexpression repressed
it (Fig. 5a). Furthermore, downstream target genes of OCT4
were increased in CHIP-depleted cells, whereas decreased
in CHIP-overexpressed cells (Supplementary Fig. S8). We
also found that CHIP depletion increased cell viability,
whereas double depletion of CHIP and OCT4 or OCT4
depletion decreased it (Fig. 5b).
Next, we analyzed side population, a cancer stemness
characteristic, after CHIP depletion or CHIP/OCT4 double
depletion in both MDA-MB231 and MCF7 cells (Fig. 5c).
Whereas side population increased after CHIP depletion,
CHIP/OCT4 double depletion or OCT4 depletion dramati-
cally decreased side population in both cells.
We also overexpressed WT OCT4 or OCT4_K284R in the
endogenous OCT4-depleted cells and measured the viability of
these cells (Fig. 5d). It was found that cell viability increased
after WT OCT4 overexpression. Moreover, the viability of cells
showing OCT4_K284R overexpression was higher than that of
cells showing WT OCT4 overexpression. Interestingly,
increased viability of WT OCT4-overexpressing cells decreased
after additional CHIP overexpression. However, the viability of
OCT4_K284R-overexpressing cells was not affected by addi-
tional CHIP overexpression.
Fig. 2 CHIP E3 ligase regulates OCT4 stability through proteasomal
degradation. a Coomassie blue-stained gel of afﬁnity-puriﬁed CHIP
complex in MDA-MB-231 cells. The Venn diagram indicates the
relationships between proteins identiﬁed in each immunoprecipitation
complex by performing mass spectrometry. b Molecular interaction
network between CHIP and OCT4 was determined by performing
IPA. c MDA-MB-231 and MCF7 cells were transfected with scramble
or CHIP siRNAs. After 48 h, mRNA (upper) and protein (lower) levels
of the indicated genes were detected by performing RT-PCR and
western blotting, respectively. d The cells were transfected with empty
and FLAG–CHIP expression vectors for 40 h and were treated with 20
μM MG132 for 8 h. e The cells were transfected with increasing
concentrations of the FLAG–CHIP expression vector for 40 h and
were treated with 20 μM CHX for 8 h. OCT4 and FLAG–CHIP levels
were detected by performing western blotting, with GAPDH as a
loading control
OCT4 ubiquitination in breast tumorigenesis 1785
Ofﬁcial journal of the Cell Death Differentiation Association
Next, we measured the side population to determine
whether OCT4_K284R affected the stemness of breast
CSCs (Fig. 5e). The side population of MDA-MB231 and
MCF7 cells increased after OCT4 overexpression, with
higher side population being observed after OCT4_K284R
overexpression than after WT-OCT4 overexpression. The
increase in the side population after WT-OCT4 over-
expression decreased after CHIP overexpression. However,
OCT4_K284R overexpression-induced increase in the side
population was not affected by CHIP overexpression. These
data indicate that CHIP induces OCT4 polyubiquitination at
K284, which affects the stability and transcriptional activity
of OCT4, a major regulator CSCs.
CHIP E3 ligase reverses OCT4 overexpression-
induced increase in tumor burden and metastasis in
a breast cancer xenograft mouse model
To examine the in vivo effect of CHIP on breast cancer
tumorigenesis, we generated stable MDA-MB231 cells and
xenografted 1 × 103 cells cultivated as mammospheres into
nude mice. It was displayed by photographs (Fig. 6a) and
tumor volume (Fig. 6b) and weight (Fig. 6c). CHIP-
overexpressing cells did not produce tumors or produced
smaller tumors than those produced by WT cells. In con-
trast, CHIP-depleted cells produced larger tumors than those
produced WT cells. Further, no tumors were produced by
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Fig. 3 CHIP E3 ligase interacts with OCT4 and induces its poly-
ubiquitination. a Interaction between CHIP and OCT4 in MDA-MB-
231 cells was detected by performing immunoprecipitation assay. b
HEK293 cells were transfected with vectors expressing WT
FLAG–CHIP or the indicated CHIP mutants K30A and H260Q and
were cotransfected with OCT4 expression vector for 40 h and were
treated with 20 μM MG132 for 8 h. Interaction of OCT4 with CHIP
(WT or mutant) was detected by performing immunoprecipitation
assay. c The cells were transfected with the indicated vectors for 40 h
and were treated with 20 μM CHX for 8 h. GAPDH was used as a
loading control. MDA-MB-231 cells were transfected with CHIP
siRNA (d), FLAG–CHIP-overexpressing vector (e), and WT or mutant
FLAG–CHIP-expressing vector (f). After 40 h, the transfected cells
were treated with 20 μM MG132 for 8 h. Cell lysates were prepared in
denaturing condition and were immunoprecipitated using anti-OCT4
antibody. OCT4 polyubiquitination was detected by performing wes-
tern blotting
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CHIP and OCT4 double depleted cells. OCT4-
overxpressing cells produced the largest tumors; however,
CHIP-overexpression in OCT4-overexpressed cells sig-
niﬁcantly decreased the size of these tumors.
Immunohistochemical analysis was performed to deter-
mine the in vivo expression of CHIP with OCT4 in xeno-
grafted tumors (Fig. 6d). We observed that reverse-
correlated between CHIP and OCT4; CHIP depletion
increased OCT4 expression and CHIP overexpression
decreased OCT4 expression in tumor sections. Furthermore,
xenografting of cells at different densities produced addi-
tional tumors similar to those produced by xenografting 1 ×
103 cells (Supplementary Fig. S9, 1 × 104 cells; Supple-
mentary Fig. S10, 1 × 105 cells).
Next, we injected the indicated cells into the tail veins of
mice and counted tumors formed in their lungs (Fig. 6e). We
observed that CHIP-overexpressing and CHIP/OCT4 double-
overexpressing cells rarely produced metastatic tumors in the
mouse lungs, whereas CHIP-depleted or OCT4-overexpressing
cells frequently produced metastatic tumors in the mouse lungs
(Supplementary Fig. S11A and S11B). However, cells showing
CHIP/OCT4 double-overexpression rarely produced metastatic
tumors. Quantiﬁcation data for tumor burden and metastasis
incidence are presented as a table (Supplementary Fig. S12).
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Fig. 4 CHIP-induced OCT4 polyubiquitination at K284 regulates
OCT4 stability. a OCT4 ubiquitination at Lys284, with di-glycine
modiﬁcation in the MS/MS spectrum. b MCF7_OCT4KD cells were
transfected with the indicated mutant vectors for 40 h, and were treated
with 20 μM MG132 for 8 h. Interaction of OCT4 (WT or mutant) with
CHIP was detected by performing immunoprecipitation assay. c The
cells were transfected with increasing concentrations of the
FLAG–CHIP-expressing vector and were cotransfected with
OCT4_K284R-expressing vector for 40 h, followed by treatment with
20 μM CHX for 8 h. Mutated OCT4 and FLAG–CHIP levels were
determined by performing western blotting, with GAPDH as a loading
control. d The cells were transfected with the indicated vectors for 40 h
and were treated with 20 μM MG132 for 8 h. Cell lysates were pre-
pared in denaturing condition and were immunoprecipitated using anti-
OCT4 antibody. OCT4 polyubiquitination was determined by per-
forming western blotting
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Furthermore, we generated the CHIP and OCT4_K284R
overexpressed MDA-MB231 cells and xenografted 1 × 103
cells cultivated as mammospheres into nude mice. It was
displayed by photographs (Fig. 6f) and tumor volume (Fig. 6g)
and weight (Fig. 6h). Compared to parent cells or CHIP
overexpressed cells, ubiquitination mutant OCT4_K284R
overexpressing cells generated the largest tumors in xeno-
grafted mice, although the cells were co-overexpression of
CHIP. These data show that OCT4 overexpression and/or
increased its protein stability could increase tumor progression
and metastasis in vivo similar to that observed in vitro.
Patients with breast cancer showing low CHIP E3
ligase expression have poor survival probability
We used an online resource and performed Kaplan–Meier
plot analysis to explore the survival probability of patients
with breast cancer who showed CHIP expression (Fig. 7a).
Patients with breast cancer who showed low CHIP expres-
sion had poor survival probability, including relapse-free,
distant metastasis-free, and post-progression survival. Fur-
thermore, Oct4 high-expressed breast cancer patients showed
the poor post-progression survival probability (Supplemen-
tary Fig. S2). Post-progression survival was calculated from
tumor progression until death and was correlated with
metastasis [21] and the most progressive status [22].
We examined the expressions of CHIP and OCT4 in 12
breast cancer patients by western blotting, respectively. In 10 of
12 breast cancer patients, CHIP expression was downregulated
in malignant tissues than in normal counterpart tissues. In
contrast, OCT4 expression was higher in malignant tissues
compared to their normal counterpart tissues in 5 of 12 breast
cancer patients (about 42%, Fig. 7b). In the OCT4 increased
patients, CHIP was downregulated in malignant tissues than in
normal counterpart tissues, about 80%. Reverse expression of
those expressions was also found in ﬁve breast cancer patient
tissues. However, we could not statistical analysis for the
correlation between CHIP and OCT4 because of shortage of
sample numbers.
Discussion
In this study, we established mammospheres from MDA-
MB231 and MCF7 breast cancer cells to characterize CSCs.
Because CSCs likely are a minority cell population among
total cancer cells, their identiﬁcation and enrichment are a
signiﬁcant challenge [7]. This indicates that stem cells from
breast tissue can be performed by the simple mammosphere
cultures that enrich highly tumorigenic CSCs, which are
probably the most dangerous cells within tumors compared
with the bulk population of tumor cells, by using a simple
in vitro culture technique. We observed that CHIP E3 ubi-
quitin ligase was signiﬁcantly downregulated in mammo-
spheres derived from MDA-MB231 and MCF7 cells
compared with that in monolayer cultured cells. We found
that CHIP directly interacted with OCT4 and decreased its
stability and breast CSC properties. OCT4, a transcription
factor encoded by POU5F1, belongs to POU family of DNA-
binding proteins [23]. These proteins regulate target gene
expression by binding to octamer motif ATGCAAAT within
promoters or enhancers. OCT4, whose expression is asso-
ciated with pluripotent properties of stem cells, is an essential
factor that controls the early stages of mammalian embry-
ogenesis. Oct4 mRNA expression level in mouse embryonic
stem cells is critical for the maintenance of pluripotency and
differentiation toward trophoblast or primitive endodermal
and mesodermal lineages. Post-translational modiﬁcation of
OCT4 is important to regulate its function and to cure dis-
eases. Protein kinase A and/or MAPK phosphorylate OCT4
at highly conserved Ser229 (murine) or Ser236 (human)
within the POU DNA-binding homeodomain [24]. Phos-
phorylation at this serine residue sterically hinders both DNA
binding and homodimer assembly. ERK1/2 phosphorylates
OCT4 at Ser111 to regulate its subcellular distribution and
degradation [25]. Small ubiquitin-related modiﬁer (SUMO)-1
targets OCT4 at Lys118 in mice [26]. Sumoylation of OCT4,
which does not alter its subnuclear localization, enhances its
stability, DNA binding, and transactivation functions. E3
ligases interact directly with OCT4 to promote ubiquitin
transfer. OCT4 ubiquitination promotes its degradation and
dramatically decreases its transcriptional activity [27–29].
WWP2, Itch, and DPF2 are E3 ubiquitin ligases that speci-
ﬁcally interact with OCT4. However, OCT4 site ubiquiti-
nated by these ligases is unclear, yet.
The present study is the ﬁrst to show that CHIP ubiqui-
tinates OCT4 at Lys284. CHIP overexpression did not
degrade mutant OCT4_K284R. Mutant OCT4_K284R
overexpression increased the proliferation and side popula-
tion of breast cancer cells. Excitingly, 1 × 103 of mutant
Fig. 5 CHIP-induced OCT4 polyubiquitination at K284 regulates cell
viability and side population. a Transcriptional activation in MCF7
cells was measured by performing the reporter assay. The cells were
transfected with OCT4 reporter vector alone or were cotransfected
with CHIP siRNA or FLAG–CHIP-expressing vector for 48 h. b, c
The cells were transfected with the indicated siRNAs alone or in
combination for 48 h, and cell viability was detected by performing
WST assay, and side population was analyzed, as described in
Materials and methods. d, e The cells were transfected with the indi-
cated expression vectors alone or in combination for 48 h and cell
viability was detected by performing WST assay, and side population
was analyzed, as described in Materials and methods. OCT4 and CHIP
levels were detected by performing western blotting, with GAPDH as
a loading control. Signiﬁcant differences are indicated by an asterisk
(*p < 0.05, **p < 0.01); p values were calculated using Student’s ttest
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OCT4_K284R overexpressed breast cancer cells drastically
generated tumor burdens in xenografted mice. These data
strongly indicate that CHIP expression decreases in CSCs
and that OCT4 dosage is critical for CSC maintenance. In
previous study, it was reported that other E3 ligase WWP and
Itch regulates OCT4 stability [27, 28]. However, E3 ligases
WWP2 and Itch may not maintain OCT4 stability in breast
CSCs because expression of these E3 ligases is upregulated
like that of OCT4 in mammosphere cultures. We believe that
different E3 ligases regulate OCT4 stability differently in ES
cells and CSCs. Therefore, we hypothesize that differential
regulation of E3 ligases is critical for CSC survival and
maintenance in tumors and needs to be examined further.
Regulation of CHIP in CSCs is unclear. Although we did
not elucidate this in the present study, we have discussed it.
Limited evidence is available on the regulation of CHIP
mRNA expression and post-translational modiﬁcation under
different physiological and pathological contexts. CHIP
mRNA expression is upregulated under various stress con-
ditions such as heat shock and oxidative damage [30, 31].
Stress-induced transcriptional regulation is important under
various physiological conditions such as neurodegenerative
disorders and heart diseases. TLR2 activation enhances CHIP
expression and activity through JNK signaling [32]. Down-
regulation of CHIP mRNA and protein expression has been
reported in malignant tissues compared with that in their
normal counterparts, including the stomach [33], pancreas
[34], and breast [11]. In MC3T3-E1 cells, miR-764-5p inhi-
bits CHIP mRNA translation by binding at its 3′-UTR [35].
CHIP is downregulated in osteoblast progenitor cells during
osteoblast differentiation. CHIP activity and stability are also
regulated through post-translational modiﬁcation. The N- and
C-terminal regions of CHIP are proposed to contain func-
tional phosphorylation sites, which should be conﬁrmed in
future studies. Association between CHIP and kinases such as
ERK5 and Lim kinase 1 has been reported [36, 37]. ERK5
activation increases CHIP ubiquitin ligase activity possibly
through a conformational change in CHIP. Phosphorylation-
dependent regulation of CHIP activity is an interesting pos-
sibility that needs further investigation. Moreover, mechan-
isms underlying decreased CHIP expression in CSCs and
association between low CHIP expression and CSC survival
should be investigated. At present, we are examining the
regulation of CHIP expression and activation in CSCs.
Thus, our results indicate that CSCs show decreased
CHIP expression and increased OCT4 stability through
post-translational modiﬁcations to maintain their
population and survival during breast cancer progres-
sion. Our results also suggest that targeting OCT4 post-
translational modiﬁcation is an ideal approach for
breast cancer therapy.
Materials and Methods
Cell culture and transfection
The human breast cancer cell lines MDA-MB-231 and MCF7
were obtained from ATCC and were maintained in Dulbecco’s
modiﬁed Eagle’s medium containing 10% fetal bovine serum
(FBS) and 1% antibiotics (Invitrogen) at 37 °C in an atmo-
sphere of 5% CO2. Transfection with CHIP, WT and mutant,
expression vectors [38] and Oct4 expression vector [39] as
well as with CHIP and Oct4 siRNA were performed with
Lipofectamine 200 and Lipofectamine RNAiMAX reagent
(Invitrogen), according to the manufacturer’s instruction.
CHIP siRNA #1 (5′-CCCAAGUUCUGCUGUUGGACU-
3′), CHIP siRNA #2 (5′-GAAGAGGAAGAAGCGAGA-
CAU-3′), CHIP siRNA #3 (5′- GCAGUCUGUGAAGGCGC
ACUU-3′), and OCT4 siRNA (5′-UUAAGUUCUUCAUU-
CACUAAG-3′) were purchased from COSMOGENETECH.
Cells were collected 2 days after the transfection for use in
subsequent experiments.
Mammosphere culture
Cells (density, 1000 cells per ml) were grown in ultra-low
attachment plates (Corning) containing mammary epithe-
lium basal medium (Lonza) supplemented with B27
(Gibco), 20 ng/ml EGF, and 20 ng/ml bFGF (PeproTech).
After culturing for 15 days, mammospheres with diameters
of >50 μm were counted.
Mutagenesis and generation of stable cell lines
Point mutation of lysine to arginine at position 284 (K284R)
in OCT4 was induced by performing site-directed mutagen-
esis. Primers used are shown in Supplementary Figure S11.
Fig. 6 CHIP overexpression decreases tumors and metastatic nodes
derived from OCT4-overexpressing cells in vivo. Nude mice were
injected with the indicated stable cell lines derived from mammo-
sphere cultured MDA-MB-231 cells (1 × 103) to form subcutaneous
xenografts. After 12 weeks, tumors were isolated and were photo-
graphed (a); their sizes (b) and weights (c) are presented in a statistical
graph. d Immunohistochemical analysis of the xenografted tumors by
using anti-CHIP and anti-OCT4 antibodies; scale bars, 100 μm. e The
indicated stable lines derived from MDA-MB-231 cells (1 × 106) were
injected into the tail vein of nude mice. After 12 weeks, mouse lungs
were isolated and node numbers were counted and presented in a
statistical graph. All animal experiments were performed using
mammospheres. Nude mice were injected with the indicated stable cell
lines derived from mammosphere cultured MDA-MB-231 cells (1 ×
103) to form subcutaneous xenografts. After 12 weeks, tumors were
isolated and were photographed (f); their sizes (g) and weights (h) are
presented in a statistical graph. The data are presented as mean ± SD
(n= 5). Signiﬁcant differences are indicated by an asterisk (*p < 0.05,
**p < 0.01); p values were calculated using Student’s ttest
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ShRNA-expressing lentiviral vectors for CHIP and OCT4
depletion (CHIPKD and OCT4KD cells) that targeted the 3ʹ-
UTR of the encoding genes were purchased from Sigma
(CHIP: TRCN0000007525, TRCN0000007526, and
TRCN0000007527; OCT4: TRCN0000235522). Lentivirus
production and stable cell line generation were performed, as
described previously [40].
Total RNA isolation and reverse transcription-
polymerase chain reaction
RNA was isolated using TRIzol® reagent (Invitrogen),
according to the manufacturer’s instructions. Reverse
transcription-polymerase chain reaction (RT-PCR) was
performed using a reverse transcription system (TOYOBO)
and primers listed in Supplementary Figure S13. PCR was
performed using instructions given in Ex-Taq (TaKaRa)
manual. qRT-PCR was performed using a SYBR Premix
(TaKaRa) and AB StepOnePlus Real-Time PCR System,
according to the manufacturer’s instructions.
Microarray analysis
Gene expression in the examined cell lines was analyzed
using high-density oligonucleotide microarrays containing
20,889 transcripts (HG-U133 Plus 2.0; Affymetrix). Target
preparation and microarray processing were performed as
described in Affymetrix GeneChip expression analysis
manual. GeneChip analysis was performed using Affyme-
trix GeneChip manual with Microarray Analysis Suite 5.0,
Data Mining Tool 2.0, and Microarray Database software.
Luciferase assay
OCT4 reporter assay was performed using OCT4 promoter
construct phOCT4-Luc [41]. MCF7 cells were transfected
A
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Fig. 7 Patients with breast cancer showing low CHIP E3 ligase
expression have poor survival probability. a Overall, relapse free,
distant metastasis and post-progression survival were analyzed with
CHIP expression level using Kaplan–Meier plot analysis. b CHIP and
OCT4 expression levels of both malignant (T) and normal (N) tissues
were detected using western blotting using western blot. β-Actin was
used a normalization control. The data are presented as mean ± SD (n
= 5). We also quantitated the protein changes of CHIP and OCT4, and
venn diagram was presented (right). Signiﬁcant differences are indi-
cated by an asterisk (*p < 0.05, **p < 0.01); p values were calculated
using Student’s t test
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with the CHIP expression vector or CHIP siRNA, and β-
galactosidase expression vector was used for normalization.
After 48 h, luciferase activity was measured using a luci-
ferase assay system (Promega), according to the manu-
facturer’s instructions.
Side population analysis
Cells were transfected with the indicated vectors or siRNAs
and were harvested after 48 h. Next, 1 × 106 cells were incu-
bated in 1ml suspension medium (HBSS, 2% FBS, and 10
mM HEPES) containing 5 μg/ml Hoechst 33342 dye (Thermo
Fisher Scientiﬁc) and 50 μMverapamil (Sigma) at 37 °C for 60
min. The cells were then washed three times with a cold sus-
pension medium and were treated with 2 μg/ml PI solution. A
minimum of 20,000 events/sample were collected using
FACSDiva and Cell Quest applications (BD Biosciences).
Cell viability analysis
Cells were grown in 96-well culture plates and were
transfected with CHIP and OCT4 siRNAs or CHIP and WT
OCT4 and OCT4_K284 expression vectors. After 48 h,
WST solution (Daeil) was added to each well. After 1–3 h
of incubation, absorbance was measured using ELISA
reader at a test wavelength of 450 nm.
Recombinant protein production and GST-pulldown
assay
GST-CHIP, GST-OCT4_WT, and GST-OCT4_K284R
were expressed in BL21 cells and puriﬁed through a
GST-pulldown assay using glutathione Sepharose 4B (GE
Healthcare). Glutathione Sepharose 4B was added to the
lysates, followed by incubation for 1 h. The samples were
washed with PBS and eluted in 10 mM reduced glutathione.
Ubiquitination assay and in vitro ubiquitination
assay
Ubiquitination assay was performed under denaturing con-
dition, as described previously [38, 42].
Recombinant proteins were incubated in 40mM Tris-HCl
(pH7.6), 50mM NaCl, and 1mM dithiothreitol with 100 ng of
an E1 (UBE1; Boston Biochem), 250 ng of an E2 (UbcH5c;
Boston Biochem), 5 μg of ubiquitin (sigma), and 2mM ATP
(Fermentas) for 3 h. The samples were boiled in 2 × SDS
buffer, OCT4 and CHIP were detected by western blotting.
Tissues
Tissue samples were obtained at biopsy from 12 breast
cancer patients and their normal counterparts from
Gangnam Severance Hospital in Korea. The protocol for
the study was approved by the institutional review board
(IRB) of the Yonsei University College of Medicine (IRB
number: 3–2014–0239). Immediately after biopsy, the
tissue samples were frozen in liquid nitrogen and stored at
−70 °C until use.
Immunoprecipitation and western blotting
Cell lysates were incubated with the following antibodies:
mouse IgG (sc-3877; Santa Cruz Biotechnology), anti-
FLAG antibody (F1804; Sigma), and anti-OCT4 antibody
(sc-5279; Santa Cruz Biotechnology). Immunoprecipitation
was performed as described previously [39].
Western blotting was performed using the following
antibodies: anti-GAPDH (sc-25778), anti-CHIP (sc-66830),
anti-Nanog (sc-33759), anti-SOX2 (sc-20088), and anti-
OCT4 antibodies (all purchased from Santa Cruz Bio-
technology); anti-FLAG antibody (Sigma); and HRP-
conjugated anti-Ub antibody (BML-PW0150; ENZO).
Proteins of interest were detected using an ECL solution
(Amersham Life Science) with LAS-3000 detector (Fuji-
ﬁlm), according to the manufacturer’s directions.
Immunohistochemistry
Xenografted tumors were obtained and ﬁxed in 4% paraf-
ormaldehyde (BIOSESANG). The ﬁxed tumors were
embedded in parafﬁn blocks and were sliced into 0.4-μm-
thick sections. CHIP and OCT4 levels in the xenografted
tumors were immunohistochemically detected using
Vectastain ABC kit and DAB substrate kit (Vector
Laboratories).
Mass spectrometry and network analysis
For identiﬁcation of CHIP-interacting proteins in MDA-
MB231, CHIP immunoprecipitation eluates were separated
by SDS-PAGE and subjected to in-gel tryptic digestion
following the general protocol [43]. Extracted peptides were
suspended in 0.1% FA in water, loaded onto an EASY-
Spray C18 column (75 µm × 50 cm, 2 µm) and separated
with a 2–35% gradient of 0.1% FA in ACN for 65 min at a
ﬂow rate of 300 nL/min. MS spectra were recorded on a Q-
Exactive hybrid quadrupole-Orbitrap mass spectrometer
(Thermo Fisher Scientiﬁc) interfaced with a nano-ultra-
HPLC system (Easy-nLC1000; Thermo Scientiﬁc). Col-
lected MS/MS raw ﬁles were converted to mzXML ﬁles
using the Trans-Proteomic Pipeline (version 4.4) and ana-
lyzed using the Sequest (version 27) algorithm in the
SORCERER (Sage-N Research, Milpitas) platform. Protein
database search was performed using the Uniprot human
database (version 2016.06, 313072 entries). Full tryptic
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speciﬁcity and up to two missed cleavage sites were
allowed. Mass tolerances for precursor ions and fragment
ions were set to 10 p.p.m. and 1 Da, respectively. Fixed
modiﬁcation for carbamidomethyl-cysteine (+ 57.0215 Da)
and variable modiﬁcations for methionine oxidation
(+15.9949 Da) were used. All proteins with a ProteinPro-
phet probability of ≥95% with minimum two peptides and a
PeptideProphet probability of ≥90%, peptide FDR ≤0.3%
were identiﬁed using Scaffold (version 4.3.2; Proteome
Software, Portland, OR, USA).
For ubiquitination site mapping of OCT4, puriﬁed
OCT4 protein from HEK293 cell line was separated by
SDS-PAGE and subjected to in-gel digestion with trypsin/
LysC mix (Promega). Collected MS/MS raw ﬁles were
analyzed using the Proteome Discoverer (version 1.4). Di-
glycine modiﬁcation (GG, +114.043 Da) on the lysine and
missed tryptic cleavage at the modiﬁed site were used.
Human database and other search parameter were set with
the same values as above.
Network analysis of selected CHIP-interacting proteins
was performed by using the Ingenuity Pathway Analysis
(IPA) software (Ingenuity System Inc, USA). Protein
interaction networks functionally associated with OCT4 and
CHIP were merged to generate a protein interaction network
constituted by OCT4 and CHIP.
Animal experiments
All animal experiments were approved by the Institutional
Review Board of the Yonsei University College of Medi-
cine and were performed in speciﬁc pathogen-free facilities
according to the university’s guidelines for the Care and
Use of Laboratory Animals (2015–0376). Xenografted mice
and mice showing lung metastasis were generated using the
cells from mammosphere culture as described previously
[44, 45].
Kaplan–Meier analysis
Kaplan–Meier analysis of survival curve was performed
using http://kmplot.com/analysis and two gene symbols
STUB1 (Affy ID: 217934_x_at) and POU5F1 (Affy ID:
208286_x_at) for patients with breast cancer.
Statistical analysis
Two tumors were isolated per mouse and were analyzed to
determine mean tumor volume per mouse. Unpaired t tests
were used to analyze mean tumor volume in the xenografted
mice. Statistical analyses were performed using Student’s t
test with GraphPad Prism software (version 6; GraphPad
Software Inc., La Jolla, CA). The data were considered
statistically signiﬁcant at p < 0.05.
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